妊娠期耐多药结核与不良出生结局的系统综述与荟萃分析
该系统综述与荟萃分析检索PubMed、Scopus和Web of Science至2020年2月,纳入12项研究、174例妊娠期耐多药结核孕妇和110例不良结局。汇总显示孕妇死亡、妊娠丢失、早产和低出生体重的合并患病率分别为7.5%、10.6%、12.9%和23.7%,提示耐多药结核与不良母胎结局高风险相关,但证据多为初步性,需前瞻性队列研究验证。
要点
- 妊娠期耐多药结核孕妇死亡合并患病率为7.5%(95%CI 3.2-12.8)。
- 妊娠丢失合并患病率为10.6%(95%CI 6.0-16.3),早产为12.9%(95%CI 0.0-38.0)。
- 低出生体重合并患病率为23.7%(95%CI 17.0-31.0),为常见不良围产结局。
核心结论
- 耐多药结核可能与不良母胎结局高风险相关,但证据多为初步性,解释需谨慎。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Scopus和Web of Science至2020年2月,纳入12项研究,含174例妊娠期耐多药结核孕妇和110例不良结局。
主要发现
- 孕妇死亡合并患病率为7.5%(95%CI 3.2-12.8)。
- 妊娠丢失合并患病率为10.6%(95%CI 6.0-16.3)。
- 早产合并患病率为12.9%(95%CI 0.0-38.0)。
- 低出生体重合并患病率为23.7%(95%CI 17.0-31.0)。
临床怎么用
- 临床应关注妊娠期耐多药结核孕妇的母胎不良结局风险,并加强监测与管理。
局限性
- 证据 largely 为初步性,需足够样本量的前瞻性队列研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is a major global public health concern. However, there is a dearth of literature on whether MDR-TB and its medications impact maternal and perinatal outcomes, and when such evidence exists the findings are conflicting. OBJECTIVES: This systematic review and meta-analysis aimed to examine the impact of MDR-TB and its medications during pregnancy on maternal and perinatal outcomes. SEARCH STRATEGY: PubMed, Scopus and Web of Science databases were searched from earliest to February 2020. SELECTION CRITERIA: Records were screened based on pre-defined selection criteria and assessed for quality by two independent reviewers. DATA COLLECTION AND ANALYSIS: A meta-analysis was performed using the random effects model to calculate pooled prevalence for each outcome. MAIN RESULTS: Of the 72 records identified, 12 were included in the systematic review and meta-analysis, consisting of 174 pregnant women with MDR-TB and 110 adverse outcomes. Maternal death, pregnancy loss, preterm birth and low birthweight were the most common maternal and perinatal adverse outcomes reported in the studies. The overall pooled prevalence was 7.5% (95% CI 3.2-12.8) for maternal death, 10.6% (95% CI 6.0-16.3) for pregnancy loss, 12.9% (95% CI 0.0-38.0) for preterm birth and 23.7% (95% CI 17.0-31.0) for low birthweight. CONCLUSIONS: The findings suggest that MDR-TB is associated with a high risk of adverse maternal and perinatal outcomes, but these should be interpreted cautiously because the evidence is largely preliminary. Adequately powered prospective cohort studies are urgently required to corroborate these findings. TWEETABLE ABSTRACT: Multidrug-resistant tuberculosis may increase the risk of adverse maternal and perinatal outcomes.
引用
- Alene KA, Jegnie A, Adane AA, et al. Multidrug-resistant tuberculosis during pregnancy and adverse birth outcomes: a systematic review and meta-analysis. BJOG. 2020. PMID: 33068306. doi:10.1111/1471-0528.16573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。